Scan how AddLife's earnings momentum compares with peers by running the hand picked list of solid balance sheet and fundamentals (199 results).
For an investor in AddLife, the core belief is that a focused Nordic life sciences supplier can keep improving profitability by pruning weaker products and leaning on higher margin areas like orthopedic surgery and advanced lab tools. The latest quarter showed earnings per share from continuing operations at SEK 1.05, which supports that margin focused story in the near term.
The next key catalyst is execution on organic growth and tenders, particularly in Labtech and Medtech, without letting working capital and inventory expansion strain cash flow. The main operational risk is that higher debt and any hit to academic or healthcare demand could squeeze flexibility just as the group is investing in new products and acquisitions.
The third quarter and nine month 2026 earnings announcement is the clearest reference point right now. Sales reached SEK 2,599 million for the quarter and SEK 7,965 million for the nine month period, with net income at SEK 127 million and SEK 384 million respectively. Earnings per share from continuing operations also tracked higher than a year earlier.
For you, that result matters because it touches both sides of the thesis. It supports the idea that AddLife can grow while improving profit quality, yet it also comes with the reminder that working capital, integration of past deals and a relatively high debt load all need close watching if the acquisition pipeline and product refreshes are to remain a positive catalyst rather than a drag.
AddLife's narrative projects SEK 13.6b revenue and SEK 825.4 million earnings by 2029. This reflects a projection of 8.3% yearly revenue growth and an earnings increase of about SEK 181 million from SEK 644.0 million today.
Discover how AddLife's fair value indicates a 12% potential upside to its current price that may not remain available for long.
Three fair value estimates from the Simply Wall St Community cluster between SEK 204.75 and about SEK 227.95 per share, yet they still span a meaningful spread for AddLife. Those retail viewpoints sit beside clear execution risks around tenders, cash conversion and research demand, so you really benefit from weighing several contrasting angles before acting.
Explore 2 other AddLife fair value estimates, including one that suggests it could be worth just SEK204.75.
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis and judgment.
If you want to stress test your AddLife thesis against other opportunities, the Simply Wall St Screener can help you scan the wider market in a structured way.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com